Advertisement
Screener

Citius Oncology, Inc. (CTOR) Auditor

Citius Oncology, Inc. Auditor

The independent registered public accounting firm that signed the audit report in each annual report on Form 10-K, newest first. PCAOB firm ID and the internal-control attestation are as tagged on the cover from fiscal 2021; earlier rows come from the signed report text.

  • 2025-12-23: Fiscal year end 2025-09-30; Auditor Wolf & Company, P.C.; PCAOB firm ID 392; Location Boston, Massachusetts.
  • 2024-12-27: Fiscal year end 2024-09-30; Auditor Wolf & Company, P.C.; PCAOB firm ID 392; Location Boston, Massachusetts.
  • 2024-04-16: Fiscal year end 2023-12-31; Auditor Marcum LLP; PCAOB firm ID 688; Location Houston, TX.
  • 2023-04-17: Fiscal year end 2022-12-31; Auditor Marcum LLP; PCAOB firm ID 688; Location West Palm Beach, Florida.
FiledFiscal year endAuditorPCAOB firm IDLocationInternal-control attestation
2025-12-232025-09-30Wolf & Company, P.C.392Boston, MassachusettsNo
2024-12-272024-09-30Wolf & Company, P.C.392Boston, MassachusettsNo
2024-04-162023-12-31Marcum LLP688Houston, TXNo
2023-04-172022-12-31Marcum LLP688West Palm Beach, FloridaNo

Similar stocks

Stock NameCountryMarket CapPE Ratio
Anixa Biosciences Inc (ANIX)United States$0.096B
Milestone Pharmaceuticals Inc. (MIST)$0.098B-2.00
ProMIS Neurosciences Inc. (PMN)$0.102B
Acrivon Therapeutics, Inc. (ACRV)United States$0.091B-1.03
Rallybio Corp (RLYB)United States$0.089B
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
ONCOLYTICS BIOTECH INC (ONCY)$0.086B
Biomea Fusion, Inc. (BMEA)United States$0.107B-3.30
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)United States$0.086B
Equillium, Inc. (EQ)United States$0.109B-11.27